Table of Contents
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
D.C. 20549
FORM 11-K
FOR ANNUAL REPORTS OF EMPLOYEE
STOCK
REPURCHASE SAVINGS AND SIMILAR
PLANS
PURSUANT TO SECTION 15(d) OF
THE
SECURITIES EXCHANGE ACT OF 1934
(
Mark One
)
x
ANNUAL REPORT PURSUANT TO SECTION 15(d) OF
THE SECURITIES EXCHANGE ACT OF 1934
For the fiscal year ended
December 31, 2009
OR
o
TRANSITION REPORT PURSUANT TO SECTION 15(d) OF
THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from
|
|
to
|
|
|
|
|
|
Commission file number
|
0-22354
|
|
|
|
|
|
|
|
A. Full title of the plan
and the address of the plan, if different from that of the issuer named below:
Martek Biosciences Corporation 401(k) Retirement
Savings Plan
B. Name of issuer of the
securities held pursuant to the plan and the address of its principal executive
office:
Martek Biosciences Corporation
6480 Dobbin Road
Columbia, Maryland 21045
Table of Contents
Martek
Biosciences Corporation 401(k) Retirement Savings Plan
December 31,
2009 and 2008
Index
Table of Contents
Report of
Independent Registered Public Accounting Firm
Board
of Trustees
Martek
Biosciences Corporation
401(k) Retirement
Savings Plan
Columbia,
Maryland
We
have audited the accompanying statements of net assets available for benefits
of Martek Biosciences Corporation 401(k) Retirement Savings Plan (the Plan) as
of December 31, 2009 and 2008,
and the related statements of changes in net assets available for benefits for
the years then ended. These financial statements are the responsibility of the
Plans management. Our responsibility is to express an opinion on these
financial statements based on our audits.
We
conducted our audits in accordance with the standards of the Public Company
Accounting Oversight Board (United States). Those standards require that we
plan and perform the audit to obtain reasonable assurance about whether the
financial statements are free of material misstatement. The Plan is not
required to have, nor were we engaged to perform, an audit of its internal
control over financial reporting. Our audits included consideration of internal
control over financial reporting as a basis for designing audit procedures that
are appropriate in the circumstances, but not for the purpose of expressing an
opinion on the effectiveness of the Plans internal control over financial
reporting. Accordingly, we express no such opinion. An audit also includes
examining, on a test basis, evidence supporting the amounts and disclosures in
the financial statements. An audit also
includes assessing the accounting principles used and significant estimates
made by management, as well as evaluating the overall financial statement
presentation. We believe that our audits provide a reasonable basis for our
opinion.
In
our opinion, the financial statements referred to above present fairly, in all
material respects, the net assets available for benefits of Martek Biosciences
Corporation 401(k) Retirement Savings Plan as of December 31, 2009 and 2008, and the changes in net assets
available for benefits for the years then ended in conformity with U.S.
generally accepted accounting principles.
Our
audits were made for the purpose of forming an opinion on the basic financial
statements taken as a whole. The accompanying supplemental schedule is
presented for the purpose of additional analysis and is not a required part of
the basic financial statements, but is supplementary information, required by
the Department of Labors Rules and Regulations for Reporting and
Disclosure under the Employee Retirement Income Security Act of 1974. This
supplemental schedule is the responsibility of the Plans management. The
supplemental schedule has been subjected to the auditing procedures applied in
the audits of the basic financial statements and, in our opinion, is presented
fairly, in all material respects, in relation to the basic financial statements
taken as a whole.
/s/
Clifton Gunderson LLP
Baltimore,
Maryland
June 22,
2010
3
Table of Contents
MARTEK BIOSCIENCES
CORPORATION
401(k) RETIREMENT
SAVINGS PLAN
STATEMENTS
OF NET ASSETS AVAILABLE FOR BENEFITS
December 31, 2009 and
2008
|
|
2009
|
|
2008
|
|
ASSETS
|
|
|
|
|
|
|
|
|
|
|
|
INVESTMENTS
|
|
|
|
|
|
Participant directed investments
|
|
$
|
24,529,420
|
|
$
|
15,957,696
|
|
|
|
|
|
|
|
RECEIVABLES
|
|
|
|
|
|
Employer
|
|
999,955
|
|
930,873
|
|
Participants
|
|
|
|
5,000
|
|
|
|
|
|
|
|
Total receivables
|
|
999,955
|
|
935,873
|
|
|
|
|
|
|
|
TOTAL ASSETS
|
|
25,529,375
|
|
16,893,569
|
|
|
|
|
|
|
|
LIABILITIES
|
|
|
|
|
|
|
|
|
|
|
|
REFUNDS OF EXCESS CONTRIBUTIONS
|
|
43,180
|
|
9,821
|
|
|
|
|
|
|
|
NET ASSETS AVAILABLE FOR
BENEFITS
|
|
$
|
25,486,195
|
|
$
|
16,883,748
|
|
The accompanying notes are
an integral part of the financial statements.
4
Table
of Contents
MARTEK BIOSCIENCES
CORPORATION
401(k) RETIREMENT
SAVINGS PLAN
STATEMENTS
OF CHANGES IN NET ASSETS AVAILABLE FOR BENEFITS
Years Ended
December 31, 2009 and 2008
|
|
2009
|
|
2008
|
|
ADDITIONS TO (DEDUCTIONS FROM)
NET ASSETS ATTRIBUTED TO:
|
|
|
|
|
|
|
|
|
|
|
|
CONTRIBUTIONS:
|
|
|
|
|
|
Participants
|
|
$
|
3,006,214
|
|
$
|
2,728,405
|
|
Employer
|
|
999,955
|
|
930,873
|
|
Rollovers
|
|
60,584
|
|
119,766
|
|
|
|
|
|
|
|
Total contributions
|
|
4,066,753
|
|
3,779,044
|
|
|
|
|
|
|
|
TRANSFER OF ASSETS
|
|
1,575,212
|
|
|
|
|
|
|
|
|
|
INVESTMENT INCOME (LOSS):
|
|
|
|
|
|
Net appreciation (depreciation) in fair value of
investments
|
|
3,628,887
|
|
(6,629,781
|
)
|
Interest on participant loans
|
|
25,144
|
|
31,193
|
|
Dividends
|
|
364,329
|
|
483,382
|
|
|
|
|
|
|
|
Total investment income (loss)
|
|
4,018,360
|
|
(6,115,206
|
)
|
|
|
|
|
|
|
Benefits paid to participants
|
|
(1,016,452
|
)
|
(961,634
|
)
|
Refunds of excess contributions
|
|
(41,426
|
)
|
(9,105
|
)
|
Fees
|
|
|
|
(4
|
)
|
|
|
|
|
|
|
NET INCREASE (DECREASE)
|
|
8,602,447
|
|
(3,306,905
|
)
|
|
|
|
|
|
|
NET ASSETS AVAILABLE FOR
BENEFITS,
BEGINNING OF YEAR
|
|
16,883,748
|
|
20,190,653
|
|
|
|
|
|
|
|
NET ASSETS AVAILABLE FOR
BENEFITS,
END OF YEAR
|
|
$
|
25,486,195
|
|
$
|
16,883,748
|
|
The accompanying notes are
an integral part of the financial statements.
5
Table of Contents
MARTEK BIOSCIENCES
CORPORATION
401(k) RETIREMENT
SAVINGS PLAN
NOTES
TO FINANCIAL STATEMENTS
December 31, 2009 and
2008
NOTE 1 DESCRIPTION OF THE PLAN
The following description of the Martek Biosciences
Corporation (the Company) 401(k) Retirement Savings Plan (the Plan) provides
only general information. Participants
should refer to the Plan document for a more complete description of the Plans
provisions.
General
The
Plan is a defined contribution plan under Section 401(k) of the Internal
Revenue Code covering all employees of the Company who are age 21 or
older. To be eligible for the Companys
discretionary matching contributions, participants must be employed at
year-end. The Plan is subject to the
provisions of the Employee Retirement Income Security Act of 1974, as amended
(ERISA). The Plan excludes from
participation, among others, certain nonresident aliens with no income from
sources within the United States of America, leased employees and self-employed
individuals as defined in the Plan document.
Effective
January 1, 2009, the Martek Biosciences Boulder Corporation 401(k) Retirement
Savings Plan (the Boulder Plan) was merged with the Plan. As such, assets totaling $1,575,212, formerly
held in the Boulder Plan, became assets of the Plan on the effective date. In
addition, employees who formerly participated in the Boulder Plan became
eligible to participate in the Plan on the effective date.
Contributions
Participants
are able to contribute to the Plan up to 100% of their annual compensation as
defined in the Plan, subject to certain limitations as determined by the
Internal Revenue Service. The Company,
the Plans sponsor, may provide a discretionary matching contribution and also
a discretionary profit sharing contribution to the Plan. During 2009 and 2008, the Company provided a discretionary matching
contribution of 50% of participant contributions up to 6% of the participants
salary.
Rollovers
from other qualified plans are permitted.
Catch-up contributions, as defined in the Plan, are permitted for
eligible participants age 50 or older.
Participant
Accounts
Each participants account is credited with the
participants contributions, the Companys contributions, and earnings from the
participants investment accounts.
Vesting
Participants
are fully vested in their voluntary contributions. Discretionary matching and profit sharing
contributions vest on a five-year graded schedule based upon the participants
length of service to the Company.
6
Table of Contents
MARTEK BIOSCIENCES
CORPORATION
401(k) RETIREMENT
SAVINGS PLAN
NOTES TO FINANCIAL
STATEMENTS
December 31, 2009 and
2008
NOTE 1 DESCRIPTION OF THE PLAN
(CONTINUED)
Investment Options
Participants
may direct the investment of their contributions into various investment
options offered by the Plan.
Loans
Participants
may borrow up to 50% of their vested account balance. The total of all loans for each participant
may not exceed $50,000. The loans are
secured by the balances in the participants accounts and bear interest at a
rate commensurate with market rates for similar loans, as defined in the
Plan. Principal and interest payments
are automatically deducted from participants semi-monthly payroll checks from
the Company.
Payment of Benefits
On
termination of service due to death, disability or retirement, a participant
may elect to receive a lump-sum amount equal to the value of the participants
vested interest in his or her account or periodic installments of such vested
interest. For termination of services
for other reasons, a participant may receive the value of the vested interest
in his or her account as a lump-sum distribution or may elect to defer payment
for vested amounts greater than $1,000.
Forfeitures
On termination of service,
unvested balances are transferred to a forfeiture account. The balance of the
forfeiture account from all participants may be used to pay administrative
expenses of the Plan. Any part of the
forfeiture account that is not used to pay expenses will be allocated among
active participants in the form of matching and/or profit sharing
contributions. For the years ended December 31, 2009 and 2008,
forfeited non-vested amounts totaled $19,658 and $26,633, respectively.
NOTE 2
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
Basis of Accounting
The accompanying financial statements have
been prepared on the accrual basis of accounting in accordance with accounting
principles generally accepted in the United States of America.
Use of Estimates in
Preparing Financial Statements
The
preparation of financial statements in conformity with accounting principles
generally accepted in the United States of America requires management to make
estimates and assumptions that affect the reported amounts of assets and
liabilities and disclosure of contingent assets and liabilities at the date of
the financial statements and the reported amounts of additions to net assets
and deductions from net assets during the reporting period. Actual results could
differ from those estimates.
7
Table of Contents
MARTEK BIOSCIENCES
CORPORATION
401(k) RETIREMENT
SAVINGS PLAN
NOTES TO FINANCIAL
STATEMENTS
December 31, 2009 and
2008
NOTE 2 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
(CONTINUED)
Investments
Investments
are reported at fair value. Fair value is defined as the price that would be
received to sell an asset in an orderly transaction between market participants
at the measurement date. See Note 8 for
discussion of fair value measurements. Purchases and sales of securities are
recorded on a trade-date basis. Interest income is recorded on the accrual
basis. Dividends are recorded on the ex-dividend date.
Expenses
Administrative
expenses of the Plan are generally paid by the Company, the Plan sponsor. Investment expenses are paid by the Plan and
included in net appreciation (depreciation) in fair value of investments. The Company provides certain accounting,
administrative, and investment management services to the Plan for which no
fees are charged.
NOTE 3
INVESTMENTS
The
following presents the Plans investments as of December 31 that represent
5% or more of the Plans net assets available for benefits:
|
|
2009
|
|
2008
|
|
|
|
|
|
|
|
Putnam Money Market Fund
|
|
$
|
2,230,908
|
|
$
|
1,628,378
|
|
|
|
|
|
|
|
Mutual Funds:
|
|
|
|
|
|
American Funds Growth Fund of America
|
|
4,484,319
|
|
2,772,543
|
|
American Funds EuroPacific Growth Fund
|
|
3,063,361
|
|
1,789,621
|
|
T. Rowe Price Equity Income Advisor Fund
|
|
2,416,865
|
|
1,617,578
|
|
Lord Abbett Small Cap Value Fund
|
|
1,554,419
|
|
990,646
|
|
Oppenheimer Strategic Income Fund
|
|
1,542,023
|
|
1,103,464
|
|
Vanguard 500 Index Trust Fund
|
|
1,487,106
|
|
*
|
|
Pimco Total Return Fund
|
|
1,470,424
|
|
*
|
|
|
|
|
|
|
|
Company Common Stock
|
|
1,426,872
|
|
2,105,291
|
|
|
|
|
|
|
|
|
|
* less than 5% threshold
8
Table of Contents
MARTEK BIOSCIENCES CORPORATION
401(k) RETIREMENT
SAVINGS PLAN
NOTES TO FINANCIAL
STATEMENTS
December 31, 2009 and
2008
NOTE 3
INVESTMENTS
(CONTINUED)
During
the years ended December 31, 2009
and 2008, the Plans investments (including gains and losses on
investments bought and sold, as well as held during the year) appreciated
(depreciated) in value as follows:
|
|
2009
|
|
2008
|
|
|
|
|
|
|
|
Company Common Stock
|
|
$
|
(806,698
|
)
|
$
|
56,571
|
|
Mutual Funds
|
|
4,435,585
|
|
(6,686,352
|
)
|
|
|
|
|
|
|
Net appreciation (depreciation) in fair value of investments
|
|
$
|
3,628,887
|
|
$
|
(6,629,781
|
)
|
NOTE 4
FEDERAL INCOME TAX STATUS
The
Company adopted a Prototype Non-Standardized 401(k) and Profit Sharing
Plan with a cash or deferral arrangement, which received a favorable
determination on August 9, 2002 from the Internal Revenue Service (the
IRS). The Plan has since been amended
and on February 18, 2009, the Plan received a determination letter from
the IRS stating that the Plan, as amended through December 31, 2008,
continues to qualify under applicable sections of the Internal Revenue Code.
Effective
January 1, 2009, several amendments were made to the Plan. Such amendments
were the exclusion of certain types of bonuses from the compensation eligible
for Plan contributions, the limitation on eligible participants to employees
who are scheduled to work at least 1,000 hours during the calendar year, and
the authorization of salary reduction contributions to be based on either a
stated dollar amount or a percentage of compensation. Management believes that the Plan, amended as
of January 1, 2009, remains qualified, and therefore, the Plan remains
exempt from taxation.
NOTE 5
RECONCILIATION OF DIFFERENCES BETWEEN THE FINANCIAL STATEMENTS AND FORM 5500
The
following is a reconciliation of net assets available for benefits per the
financial statements to the Form 5500 as of December 31, 2009 and 2008:
|
|
2009
|
|
2008
|
|
|
|
|
|
|
|
Net assets available for benefits per the
financial statements
|
|
$
|
25,486,195
|
|
$
|
16,883,748
|
|
Accrual for participants contributions receivable
|
|
|
|
(5,000
|
)
|
Accrual for employer contributions receivable
|
|
(999,955
|
)
|
(930,873
|
)
|
Accrual for refunds of excess contributions
|
|
43,180
|
|
9,821
|
|
|
|
|
|
|
|
Net assets available for benefits
per Form 5500
|
|
$
|
24,529,420
|
|
$
|
15,957,696
|
|
9
Table of Contents
MARTEK BIOSCIENCES
CORPORATION
401(k) RETIREMENT
SAVINGS PLAN
NOTES TO FINANCIAL
STATEMENTS
December 31, 2009 and
2008
NOTE 5 RECONCILIATION OF DIFFERENCES BETWEEN THE FINANCIAL STATEMENTS
AND FORM 5500
(CONTINUED)
The
following is a reconciliation of total contributions per the financial
statements to the Form 5500 as of December 31,
2009 and 2008:
|
|
2009
|
|
2008
|
|
|
|
|
|
|
|
Total contributions per the financial statements
|
|
$
|
4,066,753
|
|
$
|
3,779,044
|
|
Accrual for participants contributions receivable
|
|
|
|
(5,000
|
)
|
Prior year accrual for participants contributions
receivable
|
|
5,000
|
|
76,696
|
|
Accrual for employer contributions receivable
|
|
(999,955
|
)
|
(930,873
|
)
|
Prior year accrual for employer contributions
receivable
|
|
930,873
|
|
842,973
|
|
|
|
|
|
|
|
Total contributions per
Form 5500
|
|
$
|
4,002,671
|
|
$
|
3,762,840
|
|
The
following is a reconciliation of total deductions per the financial statements
to the total expenses per the Form 5500 as of December 31, 2009 and 2008:
|
|
2009
|
|
2008
|
|
|
|
|
|
|
|
Total deductions per the financial statements
|
|
$
|
1,057,878
|
|
$
|
970,743
|
|
Accrual for refunds of excess contributions
|
|
(43,180
|
)
|
(9,821
|
)
|
Prior year accrual for refunds of excess
contributions
|
|
9,821
|
|
3,696
|
|
|
|
|
|
|
|
Total expenses per Form 5500
|
|
$
|
1,024,519
|
|
$
|
964,618
|
|
NOTE 6
RELATED PARTY TRANSACTIONS
The Plan invests in Company common stock. In addition, certain Plan investments
represent shares of mutual funds managed by the trustee. These transactions are considered
party-in-interest transactions. These
transactions are not, however, considered prohibited transactions under ERISA
regulations.
NOTE 7 RETIRED AND SEPARATED PARTICIPANTS
At December 31, 2009 and
2008, asset allocations to retired and separated participants, which are
included in the Statements of Net Assets Available for Benefits, are $2,240,597
and $1,744,149, respectively.
10
Table of
Contents
MARTEK BIOSCIENCES CORPORATION
401(k) RETIREMENT SAVINGS PLAN
NOTES TO FINANCIAL STATEMENTS
December 31, 2009 and 2008
NOTE 8
FAIR VALUE MEASUREMENTS
The
Plan has adopted the provisions of Accounting Standards Codification Topic 820,
Fair Value Measurements and Disclosures (ASC 820), for financial
instruments. ASC 820 defines fair value, establishes a fair value hierarchy for
assets and liabilities measured at fair value and requires expanded disclosures
about fair value measurements. The
adoption of ASC 820 did not have a material impact on the Plans financial
condition or changes in net assets; however, the additional disclosures
required by ASC 820 are presented below.
The
ASC 820 hierarchy ranks the quality and reliability of inputs, or assumptions,
used in the determination of fair value and requires assets and liabilities
carried at fair value to be classified and disclosed in one of the following three
categories:
Level
1 quoted prices in active markets for identical assets and liabilities;
Level
2 inputs other than Level 1 quoted prices that are directly or indirectly observable;
and
Level
3 unobservable inputs that are not corroborated by market data.
The
Plan evaluates financial assets and liabilities subject to fair value
measurements on a recurring basis to determine the appropriate level at which
to classify them for each reporting period. This determination requires highly
subjective judgments as to the significance of inputs used in determining fair
value and where such inputs lie within the ASC 820 hierarchy.
The
Plan held certain assets that are required to be measured at fair value on a
recurring basis. These financial assets were as follows:
|
|
As of
December 31, 2009
|
|
|
|
Level 1
|
|
Level 2
|
|
Level 3
|
|
Balance
|
|
Assets
|
|
|
|
|
|
|
|
|
|
Money market fund (1)
|
|
$
|
2,230,908
|
|
$
|
|
|
$
|
|
|
$
|
2,230,908
|
|
Mutual funds (1)
|
|
|
|
|
|
|
|
|
|
Balanced
|
|
2,408,337
|
|
|
|
|
|
2,408,337
|
|
Growth
|
|
9,062,597
|
|
|
|
|
|
9,062,597
|
|
Fixed income
|
|
3,012,447
|
|
|
|
|
|
3,012,447
|
|
Value
|
|
5,960,768
|
|
|
|
|
|
5,960,768
|
|
Company stock (2)
|
|
1,426,872
|
|
|
|
|
|
1,426,872
|
|
Participant loans (3)
|
|
|
|
|
|
427,491
|
|
427,491
|
|
Total
|
|
$
|
24,101,929
|
|
$
|
|
|
$
|
427,491
|
|
$
|
24,529,420
|
|
|
|
As of
December 31, 2008
|
|
|
|
Level 1
|
|
Level 2
|
|
Level 3
|
|
Balance
|
|
Assets
|
|
|
|
|
|
|
|
|
|
Cash
|
|
$
|
1,279
|
|
$
|
|
|
$
|
|
|
$
|
1,279
|
|
Money market fund (1)
|
|
1,628,378
|
|
|
|
|
|
1,628,378
|
|
Mutual funds (1)
|
|
11,847,938
|
|
|
|
|
|
11,847,938
|
|
Company stock (2)
|
|
2,105,291
|
|
|
|
|
|
2,105,291
|
|
Participant loans (3)
|
|
|
|
|
|
374,810
|
|
374,810
|
|
Total
|
|
$
|
15,582,886
|
|
$
|
|
|
$
|
374,810
|
|
$
|
15,957,696
|
|
(1) Valued
at the net asset value as reported on the active market of shares held by the
Plan at year end.
(2) Valued
at the closing price reported on the NASDAQ Stock Market.
(3) Valued
at amortized cost, which approximates fair value.
11
Table of Contents
MARTEK BIOSCIENCES CORPORATION
401(k) RETIREMENT SAVINGS PLAN
NOTES TO FINANCIAL STATEMENTS
December 31, 2009 and 2008
NOTE 8
FAIR VALUE MEASUREMENTS
(CONTINUED)
The
table below provides a reconciliation of the beginning and ending balances of
the Plans participant loans measured at fair value using significant
unobservable inputs (Level 3) for the year ended December 31, 2009:
Balance on January 1,
2009
|
|
$
|
374,810
|
|
|
|
|
|
Transfers to (from) Level
3
|
|
|
|
Realized gains (losses)
|
|
|
|
Unrealized gains (losses)
|
|
|
|
Purchases, sales, issuances
and settlements, net
|
|
52,681
|
|
Balance on December 31, 2009
|
|
$
|
427,491
|
|
The
table below provides a reconciliation of the beginning and ending balances of
the Plans participant loans measured at fair value using significant
unobservable inputs (Level 3) for the year ended December 31, 2008:
Balance on January 1,
2008
|
|
$
|
410,872
|
|
|
|
|
|
Transfers to (from) Level
3
|
|
|
|
Realized gains (losses)
|
|
|
|
Unrealized gains (losses)
|
|
|
|
Purchases, sales,
issuances and settlements, net
|
|
(36,062
|
)
|
Balance on December 31, 2008
|
|
$
|
374,810
|
|
NOTE 9
PLAN TERMINATION
Although
it has not expressed any intent to do so, the Company has the right under the
Plan to terminate the Plan subject to the provisions of ERISA. In the event of Plan termination,
participants would become fully vested in their employer contributions.
12
Table of Contents
MARTEK BIOSCIENCES CORPORATION
401(k) RETIREMENT SAVINGS PLAN
NOTES TO FINANCIAL STATEMENTS
December 31, 2009 and 2008
NOTE 10
RISKS AND UNCERTAINTIES
The
Plan, as directed by participants, may invest in various types of investment
securities. Investment securities are
exposed to various risks, such as interest rate, market, and credit risks. Due to the level of risk associated with
certain investment securities, it is possible that changes in the values of
investment securities may occur in the near term and that such changes could
materially affect the amounts reported in the Statement of Net Assets Available
for Plan Benefits.
This information is an integral part of the accompanying financial
statements.
13
Table of Contents
MARTEK BIOSCIENCES CORPORATION
401(k) RETIREMENT SAVINGS PLAN
Form 5500, Schedule H, Part IV,
Line 4i -
Schedule of Assets (Held at End of Year)
As of December 31, 2009
EIN #52-1399362
Plan #001
|
Identity of Issue, Borrower, Lessor or
Similar Party
|
|
Fair Value
|
|
|
|
|
|
|
*
|
Putnam
Money Market Fund
|
|
$
|
2,230,908
|
|
|
|
|
|
|
|
Mutual
Funds:
|
|
|
|
|
American
Funds Growth Fund of America
|
|
4,484,319
|
|
|
American
Funds EuroPacific Growth Fund
|
|
3,063,361
|
|
|
T.
Rowe Price Equity Income Advisor Fund
|
|
2,416,865
|
|
|
Lord
Abbett Small Cap Value Fund
|
|
1,554,419
|
|
|
Oppenheimer
Strategic Income Fund
|
|
1,542,023
|
|
|
Vanguard
500 Index Trust Fund
|
|
1,487,106
|
|
|
Pimco
Total Return Fund
|
|
1,470,424
|
|
*
|
Putnam
Mid Cap Value Fund
|
|
1,065,528
|
|
|
MSIF
Trust Mid Cap Growth
|
|
948,161
|
|
|
CRM
Mid Cap Value Fund
|
|
867,056
|
|
|
Lazard
Emerging Markets Portfolio
|
|
191,506
|
|
|
ING
Global REIT Fund
|
|
56,900
|
|
|
T.
Rowe Price Retirement Income Fund
|
|
128,676
|
|
|
T.
Rowe Price Retirement 2005 Fund
|
|
65,282
|
|
|
T.
Rowe Price Retirement 2010 Fund
|
|
107,725
|
|
|
T.
Rowe Price Retirement 2015 Fund
|
|
281,316
|
|
|
T.
Rowe Price Retirement 2020 Fund
|
|
70,610
|
|
|
T.
Rowe Price Retirement 2025 Fund
|
|
76,116
|
|
|
T.
Rowe Price Retirement 2030 Fund
|
|
159,527
|
|
|
T.
Rowe Price Retirement 2035 Fund
|
|
153,542
|
|
|
T.
Rowe Price Retirement 2040 Fund
|
|
71,882
|
|
|
T.
Rowe Price Retirement 2045 Fund
|
|
154,306
|
|
|
T.
Rowe Price Retirement 2050 Fund
|
|
19,607
|
|
|
T.
Rowe Price Retirement 2055 Fund
|
|
7,892
|
|
|
|
|
|
|
*
|
Company
Common Stock
|
|
1,426,872
|
|
|
|
|
|
|
|
Participant
loans, interest rate 3.25% to 8.25%, various maturities
|
|
427,491
|
|
|
|
|
|
|
|
Total investments
|
|
$
|
24,529,420
|
|
* Represents a party-in-interest to the Plan.
15
Table of Contents
Exhibits
The
following exhibit is attached to this Annual Report on Form 11-K.
Exhibit
Number
|
|
Description of Exhibit
|
|
|
|
23.1
|
|
Consent
of Clifton Gunderson LLP, Independent Registered Public Accounting Firm
|
16
Table of Contents
SIGNATURE
Pursuant
to the requirements of the Securities Exchange Act of 1934, the trustees (or
other persons who administer the employee benefit plan) have duly caused this
annual report to be signed on its behalf by the undersigned hereunto duly
authorized.
|
MARTEK
BIOSCIENCES CORPORATION
|
|
401(k) RETIREMENT
SAVINGS PLAN
|
|
|
|
|
By:
|
/s/
Peter L. Buzy
|
|
|
|
|
Name:
Peter L. Buzy
|
|
|
|
Title:
Trustee
|
Date: June 23, 2010
17
Table of Contents
EXHIBIT INDEX
Exhibit Number
|
|
Description of Exhibit
|
|
|
|
23.1
|
|
Consent of Clifton
Gunderson LLP, Independent Registered Public Accounting Firm
|
18
Martek (NASDAQ:MATK)
Historical Stock Chart
From Jun 2024 to Jul 2024
Martek (NASDAQ:MATK)
Historical Stock Chart
From Jul 2023 to Jul 2024